HomeCompareNIOVF vs MRK

NIOVF vs MRK: Dividend Comparison 2026

NIOVF yields 9389.67% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NIOVF wins by $29652364190233612.00M in total portfolio value
10 years
NIOVF
NIOVF
● Live price
9389.67%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29652364190233612.00M
Annual income
$29,043,889,991,112,714,000,000.00
Full NIOVF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NIOVF vs MRK

📍 NIOVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNIOVFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NIOVF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NIOVF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NIOVF
Annual income on $10K today (after 15% tax)
$798,122.07/yr
After 10yr DRIP, annual income (after tax)
$24,687,306,492,445,807,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NIOVF beats the other by $24,687,306,492,445,807,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NIOVF + MRK for your $10,000?

NIOVF: 50%MRK: 50%
100% MRK50/50100% NIOVF
Portfolio after 10yr
$14826182095116806.00M
Annual income
$14,521,944,995,556,357,000,000.00/yr
Blended yield
97.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NIOVF
No analyst data
Altman Z
-9.0
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NIOVF buys
0
MRK buys
0
No recent congressional trades found for NIOVF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNIOVFMRK
Forward yield9389.67%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$29652364190233612.00M$56.8K
Annual income after 10y$29,043,889,991,112,714,000,000.00$9,798.13
Total dividends collected$29611830854875112.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NIOVF vs MRK ($10,000, DRIP)

YearNIOVF PortfolioNIOVF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$949,667$938,967.14$11,206$366.19+$938.5KNIOVF
2$84,353,175$83,337,030.95$12,650$502.35+$84.34MNIOVF
3$7,008,317,024$6,918,059,127.47$14,407$694.19+$7008.30MNIOVF
4$544,670,195,710$537,171,296,494.19$16,585$967.82+$544670.18MNIOVF
5$39,599,349,640,156$39,016,552,530,745.70$19,342$1,363.89+$39599349.62MNIOVF
6$2,693,431,305,051,366$2,651,060,000,936,399.50$22,913$1,947.19+$2693431305.03MNIOVF
7$171,402,817,083,723,070$168,520,845,587,318,100.00$27,662$2,823.89+$171402817083.70MNIOVF
8$10,206,035,765,188,530,000$10,022,634,750,908,946,000.00$34,159$4,173.35+$10206035765188.50MNIOVF
9$568,667,475,813,928,340,000$557,747,017,545,176,500,000.00$43,337$6,308.80+$568667475813928.25MNIOVF
10$29,652,364,190,233,613,000,000$29,043,889,991,112,714,000,000.00$56,776$9,798.13+$29652364190233612.00MNIOVF

NIOVF vs MRK: Complete Analysis 2026

NIOVFStock

Plato Gold Corp., a junior exploration company, engages in the exploration, evaluation, and development of gold and rare mineral properties in Canada. It holds 100% interest in the Good Hope Niobium project comprising 254 claims, which include 227 single cell mining claims and 27 boundary cell mining claims covering an area of approximately 5,146 hectares located in northwest of Marathon, Ontario. The company also has an option to acquire a 100% interest in the Pic River Platinum Group Metals project comprising 111 single cell mining claims covering an area of approximately 2,247 hectares located in Marathon, Ontario; and the Lolita project, which includes three adjoining concessions located in Southern Argentina. In addition, it holds interest in the Timmins Gold project that comprise of four properties, including the Guibord, Harker, and Holloway properties that include 4 mining leases; and the Marriott property comprising 98 claims located in east of Timmins. The company is based in Toronto, Canada.

Full NIOVF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NIOVF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NIOVF vs SCHDNIOVF vs JEPINIOVF vs ONIOVF vs KONIOVF vs MAINNIOVF vs JNJNIOVF vs ABBVNIOVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.